Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.

Conclusions: In the adjuvant setting, higher pazopanib Ctrough was associated with improved DFS, and did not increase treatment discontinuations or grade 3/4 AEs with the exception of hypertension.
PMID: 29330204 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 12, 2018 Category: Cancer & Oncology Authors: Sternberg C, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy MA, Baneyx G, Banerjee H, Aimone P, Motzer RJ Tags: Clin Cancer Res Source Type: research